In Brief: Immunomedics' CEA-Scan

Executive Summary

Immunomedics' CEA-Scan: Receives "approvable" status at FDA April 9. The colorectal cancer diagnostic imaging product will be marketed in the U.S. by the Mallinckrodt Group under an agreement announced April 9. Under terms of the agreement, Mallinckrodt will market, sell and distribute CEA-Scan on a consignment basis, while Immunomedics will retain manufacturing rights and will participate in marketing, including possible additional financing. Mallinckrodt Medical has European marketing rights under an agreement signed last year...